Literature DB >> 28283844

Long term survival and cardiopulmonary outcome in children with Hurler syndrome after haematopoietic stem cell transplantation.

Su Han Lum1, Karolina M Stepien2, Arunabha Ghosh3, Alexander Broomfield3, Heather Church3, Jean Mercer3, Simon Jones3, Robert Wynn4.   

Abstract

Premature death in untreated children with Hurler syndrome (HS) in the first decade of life is largely due to life-threatening cardiopulmonary complications. We examined the long-term survival and cardiopulmonary outcome in 54 children undergoing haematopoietic stem cell transplantation (HSCT) at the Royal Manchester Children's Hospital from 1985 to 2008. The median age at first HSCT was 15.1 months. Eighteen had graft failure and nine died after first HSCT. Of 18 patients with graft failure, 17 underwent second HSCT and the remaining one was lost to follow-up (LOF). Twelve were alive-and-engrafted after second HSCT. The overall survival at one year and 20-years was the same at 73.7%. Six children were followed up at the referral centers and excluded from cardiopulmonary endpoint review. Of the 33 evaluable children for the cardiopulmonary endpoints, nine (27.3%) had normal cardiac assessment. Of the four children on angiotensin-converting-enzyme inhibitors, two had mild cardiomyopathy and two had aortic valvular replacement. Twenty (60%) had mild/moderate mitral and/or aortic insufficiencies. Two had overnight hypoxia needing nocturnal non-invasive support. Enzyme level and donor chimerism are important predictors of long-term cardiac outcome.

Entities:  

Mesh:

Year:  2017        PMID: 28283844     DOI: 10.1007/s10545-017-0034-6

Source DB:  PubMed          Journal:  J Inherit Metab Dis        ISSN: 0141-8955            Impact factor:   4.982


  19 in total

Review 1.  Novel approaches and mechanisms in hematopoietic stem cell gene therapy.

Authors:  Brian W Bigger; Robert F Wynn
Journal:  Discov Med       Date:  2014-04       Impact factor: 2.970

2.  Chromosomal localization of the human alpha-L-iduronidase gene (IDUA) to 4p16.3.

Authors:  H S Scott; L J Ashton; H J Eyre; E Baker; D A Brooks; D F Callen; G R Sutherland; C P Morris; J J Hopwood
Journal:  Am J Hum Genet       Date:  1990-11       Impact factor: 11.025

3.  Enzyme replacement is associated with better cognitive outcomes after transplant in Hurler syndrome.

Authors:  Julie B Eisengart; Kyle D Rudser; Jakub Tolar; Paul J Orchard; Teresa Kivisto; Richard S Ziegler; Chester B Whitley; Elsa G Shapiro
Journal:  J Pediatr       Date:  2012-09-10       Impact factor: 4.406

4.  Combined enzyme replacement and haematopoietic stem cell transplantation in Hurler syndrome.

Authors:  Sunita Bijarnia; Peter Shaw; Anne Vimpani; Robert Smith; Verity Pacey; Helen O'Grady; John Christodoulou; David Sillence
Journal:  J Paediatr Child Health       Date:  2009 Jul-Aug       Impact factor: 1.954

5.  Compounding naltrexone for the treatment of autism.

Authors:  Tom Wynn; Sarah Brunetti
Journal:  Int J Pharm Compd       Date:  2009 Jul-Aug

6.  Improved metabolic correction in patients with lysosomal storage disease treated with hematopoietic stem cell transplant compared with enzyme replacement therapy.

Authors:  Robert F Wynn; J Ed Wraith; Jean Mercer; Anne O'Meara; Karen Tylee; Margaret Thornley; Heather J Church; Brian W Bigger
Journal:  J Pediatr       Date:  2009-04       Impact factor: 4.406

7.  The prevalence of and survival in Mucopolysaccharidosis I: Hurler, Hurler-Scheie and Scheie syndromes in the UK.

Authors:  David Moore; Martin J Connock; Ed Wraith; Christine Lavery
Journal:  Orphanet J Rare Dis       Date:  2008-09-16       Impact factor: 4.123

Review 8.  The cell biology of disease: lysosomal storage disorders: the cellular impact of lysosomal dysfunction.

Authors:  Frances M Platt; Barry Boland; Aarnoud C van der Spoel
Journal:  J Cell Biol       Date:  2012-11-26       Impact factor: 10.539

Review 9.  Microglia: the effector cell for reconstitution of the central nervous system following bone marrow transplantation for lysosomal and peroxisomal storage diseases.

Authors:  W Krivit; J H Sung; E G Shapiro; L A Lockman
Journal:  Cell Transplant       Date:  1995 Jul-Aug       Impact factor: 4.139

10.  Outcomes of hematopoietic stem cell transplantation for Hurler's syndrome in Europe: a risk factor analysis for graft failure.

Authors:  J J Boelens; R F Wynn; A O'Meara; P Veys; Y Bertrand; G Souillet; J E Wraith; A Fischer; M Cavazzana-Calvo; K W Sykora; P Sedlacek; A Rovelli; C S P M Uiterwaal; N Wulffraat
Journal:  Bone Marrow Transplant       Date:  2007-05-28       Impact factor: 5.483

View more
  14 in total

1.  Genetic testing of Mucopolysaccharidoses disease using multiplex PCR- based panels of STR markers: in silico analysis of novel mutations.

Authors:  Mehdi Shafaat; Mehrdad Hashemi; Ahmad Majd; Maryam Abiri; Sirous Zeinali
Journal:  Metab Brain Dis       Date:  2019-06-24       Impact factor: 3.584

Review 2.  Hematopoietic Stem Cell Transplantation for Mucopolysaccharidoses: Past, Present, and Future.

Authors:  Madeleine Taylor; Shaukat Khan; Molly Stapleton; Jianmin Wang; Jing Chen; Robert Wynn; Hiromasa Yabe; Yasutsugu Chinen; Jaap Jan Boelens; Robert W Mason; Francyne Kubaski; Dafne D G Horovitz; Anneliese L Barth; Marta Serafini; Maria Ester Bernardo; Hironori Kobayashi; Kenji E Orii; Yasuyuki Suzuki; Tadao Orii; Shunji Tomatsu
Journal:  Biol Blood Marrow Transplant       Date:  2019-02-14       Impact factor: 5.742

Review 3.  Lysosomal Acid Lipase Deficiency: Therapeutic Options.

Authors:  Gregory M Pastores; Derralynn A Hughes
Journal:  Drug Des Devel Ther       Date:  2020-02-11       Impact factor: 4.162

4.  Burden of Morbidity after Allogeneic Blood or Marrow Transplantation for Inborn Errors of Metabolism: A BMT Survivor Study Report.

Authors:  Aman Wadhwa; Yanjun Chen; Lindsey Hageman; Elizabeth Schlichting; Erin Funk; Jessica Hicks; Nora Balas; Arianna Siler; Jessica Wu; Liton Francisco; Anna Holmqvist; Ashish Gupta; Troy Lund; Paul J Orchard; Saro Armenian; Mukta Arora; Smita Bhatia
Journal:  Transplant Cell Ther       Date:  2021-12-05

Review 5.  Therapeutic Options for Mucopolysaccharidoses: Current and Emerging Treatments.

Authors:  Kazuki Sawamoto; Molly Stapleton; Carlos J Alméciga-Díaz; Angela J Espejo-Mojica; Juan Camilo Losada; Diego A Suarez; Shunji Tomatsu
Journal:  Drugs       Date:  2019-07       Impact factor: 11.431

6.  Lysosomal diseases: Overview on current diagnosis and treatment.

Authors:  Fabiano de Oliveira Poswar; Filippo Vairo; Maira Burin; Kristiane Michelin-Tirelli; Ana Carolina Brusius-Facchin; Francyne Kubaski; Carolina Fischinger Moura de Souza; Guilherme Baldo; Roberto Giugliani
Journal:  Genet Mol Biol       Date:  2019-04-25       Impact factor: 1.771

Review 7.  Hematopoietic Stem Cell Transplantation in Inborn Errors of Metabolism.

Authors:  Emily Y Tan; Jaap Jan Boelens; Simon A Jones; Robert F Wynn
Journal:  Front Pediatr       Date:  2019-10-25       Impact factor: 3.418

8.  The factors affecting lipid profile in adult patients with Mucopolysaccharidosis.

Authors:  Karolina M Stepien; Fiona J Stewart; Chris J Hendriksz
Journal:  Mol Genet Metab Rep       Date:  2017-05-18

9.  Critical clinical situations in adult patients with Mucopolysaccharidoses (MPS).

Authors:  Karolina M Stepien; Anait K Gevorkyan; Christian J Hendriksz; Tinatin V Lobzhanidze; Jordi Pérez-López; Govind Tol; Mireia Del Toro Riera; Nato D Vashakmadze; Christina Lampe
Journal:  Orphanet J Rare Dis       Date:  2020-05-14       Impact factor: 4.123

10.  Lower Exposure to Busulfan Allows for Stable Engraftment of Donor Hematopoietic Stem Cells in Children with Mucopolysaccharidosis Type I: A Case Report of Four Patients.

Authors:  Praveen Shukla; Christopher C Dvorak; Janel Long-Boyle; Sandhya Kharbanda
Journal:  Int J Mol Sci       Date:  2020-08-06       Impact factor: 5.923

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.